We are live on
!
Find out more
PAP
Persistent Asset Partners Portfolio holdings
AUM
$268M
1-Year Est. Return
158.98%
This Fund
S&P 500
This Quarter
Est. Return
+1.66%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$121M
AUM Growth
–
Cap. Flow
+$112M
Cap. Flow
% of AUM
92.95%
Top 10 Holdings %
Top 10 Hldgs %
42.01%
Holding
143
New
143
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Humana
HUM
|
+$10.2M |
| 2 |
DaVita
DVA
|
+$6.77M |
| 3 |
UnitedHealth
UNH
|
+$6.72M |
| 4 |
Pennant Group
PNTG
|
+$5.2M |
| 5 |
Cardinal Health
CAH
|
+$3.95M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 67.79% |
| 2 | Financials | 23.65% |
| 3 | Energy | 1.95% |
| 4 | Materials | 1.84% |
| 5 | Consumer Discretionary | 1.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Old Second Bancorp
OSBC
$1.22B
| $1.28M | 1.07% |
+68,343
| New | +$1.19M |
|
27
QCR Holdings
QCRH
$1.63B
| $1.21M | 1% |
+15,532
| New | +$1.31M |
|
28
Goldman Sachs
GS
$314B
| $1.19M | 0.99% |
+1,864
| New | +$1.04M |
|
29
Eli Lilly
LLY
$1.05T
| $1.19M | 0.99% |
+1,468
| New | +$1.22M |
|
30
Ascendis Pharma A/S
ASND
$17.1B
| $1.17M | 0.97% |
+8,940
| New | +$1.18M |
|
|
SLNO
31
DELISTED
Soleno Therapeutics
SLNO
| $1.1M | 0.91% |
+21,809
| New | +$1.13M |
|
|
BPMC
32
DELISTED
Blueprint Medicines
BPMC
| $1.09M | 0.9% |
+9,693
| New | +$888K |
|
33
Rhythm Pharmaceuticals
RYTM
$7.31B
| $1.09M | 0.9% |
+18,312
| New | +$1.01M |
|
34
Robinhood
HOOD
$89.7B
| $1.06M | 0.88% |
+20,315
| New | +$656K |
|
35
SoFi Technologies
SOFI
$22.2B
| $1.02M | 0.85% |
+64,600
| New | +$839K |
|
36
Wells Fargo
WFC
$265B
| $979K | 0.81% |
+12,428
| New | +$849K |
|
37
Eldorado Gold
EGO
$7.28B
| $977K | 0.81% |
+64,120
| New | +$1.06M |
|
38
Insmed
INSM
$23.5B
| $957K | 0.79% |
+12,500
| New | +$900K |
|
39
First Horizon
FHN
$12.2B
| $952K | 0.79% |
+43,492
| New | +$818K |
|
40
Equity Bancshares
EQBK
$1.04B
| $948K | 0.79% |
+21,746
| New | +$967K |
|
41
Pathward Financial
CASH
$1.89B
| $842K | 0.7% |
+10,558
| New | +$805K |
|
42
Tarsus Pharmaceuticals
TARS
$2.61B
| $832K | 0.69% |
+15,477
| New | +$703K |
|
43
Cenovus Energy
CVE
$52.1B
| $825K | 0.68% |
+57,041
| New | +$917K |
|
44
International Bancshares
IBOC
$4.76B
| $819K | 0.68% |
+12,425
| New | +$824K |
|
45
Hudbay
HBM
$9.04B
| $758K | 0.63% |
+92,022
| New | +$825K |
|
46
Apogee Therapeutics
APGE
$10.1B
| $742K | 0.62% |
+17,940
| New | +$915K |
|
47
Graphic Packaging
GPK
$3.2B
| $717K | 0.6% |
+26,147
| New | +$756K |
|
|
LNW
48
DELISTED
Light & Wonder
LNW
| $710K | 0.59% |
+7,941
| New | +$744K |
|
49
TG Therapeutics
TGTX
$8.4B
| $709K | 0.59% |
+22,366
| New | +$642K |
|
50
SouthState Bank Corp
SSB
$10.1B
| $656K | 0.54% |
+6,210
| New | +$640K |
|
Similar funds
VC
AL
FC
NF
PF
UI
SSWM
AC
Persistent Asset Partners's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Persistent Asset Partners, which disclosed 143 positions worth $121M. Its ten largest holdings account for 42% of the portfolio.
Its largest position is Humana: 38,160 shares worth $11.2M.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, followed by Financials and Energy.
- Persistent Asset Partners's largest Q4 2024 buy was Humana: 38,160 shares worth $11.2M.
- Persistent Asset Partners's ten largest holdings make up 42% of its $121M portfolio in Q4 2024.
- Persistent Asset Partners disclosed 143 positions in Q4 2024, its first 13F filing on record.
Based on Persistent Asset Partners's 13F filing for Q4 2024, filed 14 Feb 2025.